These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9566460)

  • 21. Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven?
    Briggs AH; Levy AR
    Pharmacoeconomics; 2006; 24(11):1079-86. PubMed ID: 17067193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Better analysis for better decisions: has pharmacoeconomics come of age?
    Drummond M; Sculpher M
    Pharmacoeconomics; 2006; 24(2):107-8. PubMed ID: 16460132
    [No Abstract]   [Full Text] [Related]  

  • 23. [Pharmacoeconomic impact of compliance].
    Agh T; Mészáros A
    Acta Pharm Hung; 2010; 80(2):75-80. PubMed ID: 20684381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug development means economics in the end.
    Senn S
    BMJ; 2001 Mar; 322(7287):675. PubMed ID: 11291652
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmaceuticals and medical devices: business practices.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-35. PubMed ID: 22423396
    [No Abstract]   [Full Text] [Related]  

  • 26. Ex post value reimbursement for pharmaceuticals.
    Gravelle HS
    Med Decis Making; 1998; 18(2 Suppl):S27-38. PubMed ID: 9566465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria.
    Postma MJ; Boersma C; Gansevoort RT
    Nephrol Dial Transplant; 2008 Apr; 23(4):1103-6. PubMed ID: 17210586
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-18. PubMed ID: 18345557
    [No Abstract]   [Full Text] [Related]  

  • 29. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoeconomics: historical perspective.
    Bootman JL; McGhan WF; Townsend RJ
    Ann Pharmacother; 2006 Mar; 40(3):518-9. PubMed ID: 16478813
    [No Abstract]   [Full Text] [Related]  

  • 31. Qualitative factors underlying the successful investment in new ophthalmic pharmaceutical products in the United States.
    Stewart WC; Chaney PG; Stewart JA; Kruft B; Nelson LA
    Acta Ophthalmol; 2013 Sep; 91(6):e496-7. PubMed ID: 23834660
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmaceuticals and medical devices: business practices. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
    [No Abstract]   [Full Text] [Related]  

  • 33. Applying patient outcomes and pharmacoeconomics in patient care. Proceedings of a conference. Boston, Massachusetts, September 1994.
    Am J Health Syst Pharm; 1995 Jul; 52(14 Suppl 3):S1-5. PubMed ID: 7552910
    [No Abstract]   [Full Text] [Related]  

  • 34. Is there a need for an independent centre for pharmacoeconomics in the UK?
    Walley T; Edwards RT
    Pharmacoeconomics; 1994 Feb; 5(2):93-100. PubMed ID: 10146902
    [No Abstract]   [Full Text] [Related]  

  • 35. Guidelines for measuring the costs and consequences of adopting new pharmaceutical products: are they on track?
    Pausjenssen AM; Detsky AS
    Med Decis Making; 1998; 18(2 Suppl):S19-22. PubMed ID: 9566463
    [No Abstract]   [Full Text] [Related]  

  • 36. The economics of contraceptives R&D.
    Djerassi C
    Science; 1996 Jun; 272(5270):1858-9. PubMed ID: 8658149
    [No Abstract]   [Full Text] [Related]  

  • 37. Beyond AWP . . . way beyond.
    Willke RJ
    Value Health; 2010; 13(1):1. PubMed ID: 19912595
    [No Abstract]   [Full Text] [Related]  

  • 38. What's in a perspective?
    Glick HA
    Value Health; 2010; 13(1):2. PubMed ID: 19912594
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug costs threaten patent protection.
    Cimons M
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract]   [Full Text] [Related]  

  • 40. Patent cliff mitigation strategies: giving new life to blockbusters.
    Kakkar AK
    Expert Opin Ther Pat; 2015; 25(12):1353-9. PubMed ID: 26372691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.